NERV Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases...

Stats
Dagens volum	8 736.00
Gjennomsnittsvolum	121 078
Markedsverdi	16.43M
EPS	$0 ( 2024-03-13 )
Neste inntjeningsdato	( $-1.010 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.510
ATR14	$0.0190 (0.81%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-04	Luthringer Remy	Buy	100 450	Employee Stock Option (right to buy)
2023-10-04	Race Geoff	Buy	87 050	Employee Stock Option (right to buy)
2023-10-04	Ahlholm Frederick W	Buy	42 850	Employee Stock Option (right to buy)
2023-09-27	Hasler Hans Peter	Buy	12 500	Stock Option (right to buy)
2023-09-27	Van Heek G Jan	Buy	12 500	Stock Option (right to buy)

INSIDER POWER
34.34
Last 97 transactions
Buy: 4 702 257 \| Sell: 460 450

Minerva Neurosciences Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Minerva Neurosciences Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-30 982.00 (0.00 %)
EPS:	$-4.61

FY	2023
Omsetning:	$0
Bruttogevinst:	$-30 982.00 (0.00 %)
EPS:	$-4.61

FY	2022
Omsetning:	$0
Bruttogevinst:	$-8 513.00 (0.00 %)
EPS:	$-7.30

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-9.76

Financial Reports:

No articles found.

Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.